Natalizumab for active Crohn's disease

Ghosh, S.
July 2003
Gut;Jul2003, Vol. 52 Issue 7, p1068
Academic Journal
Discusses the article 'Natalizumab for Active Crohn's Disease,' by S. Ghosh, E. Goldin, F.H. Gordon et al, published in a 2003 issue of 'New England Journal of Medicine.'


Related Articles

  • Mesalamine for Crohn's disease improves quality of life.  // Modern Medicine;Oct95, Vol. 63 Issue 10, p50 

    Presents an abstract of the article `Quality-of-Life Results of Double-Blind, Placebo-Controlled Trial of Mesalamine in Patients With Crohn's Disease,' by J.W. Singleton, S. Hanauer and M. Robinson which was featured in a science journal dated May 1995.

  • Olsalazine was not better than placebo in maintaining remission in inactive Crohn disease. Luthra, Gurinder; Pasricha, P. Jay // ACP Journal Club;May/Jun2002, Vol. 136 Issue 3, p92 

    Comments on a study which discovered that olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis. Comparison of the effects of olsalazine and placebo on patients; Assessment of adverse events in patients; Effects of mesalamine on patients.

  • GSK, ChemoCentryx Move to Phase III with Crohn's Drug. Powers, Marie // BioWorld Today;1/13/2011, Vol. 22 Issue 9, p1 

    The article reports on an initial induction study by ChemoCentryx Inc. and GlaxoSmithKline plc which compared Traficet-EN (CCX282-B) or GSK1605786 to placebo in treating patient with Crohn's disease. As reported, this Phase III study is being conducted through the Center of Excellence for...

  • Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. Colombel, Jean Fr�d�ric; Sandborn, William J.; Reinisch, Walter; Mantzaris, Gerassimos J.; Kornbluth, Asher; Rachmilewitz, Daniel; Lichtiger, Simon; D'Haens, Geert; Diamond, Robert H.; Broussard, Delma L.; Tang, Kezhen L.; van der Woude, C. Janneke; Rutgeerts, Paul // New England Journal of Medicine;4/15/2010, Vol. 362 Issue 15, p1383 

    Background: The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown. Methods: In this randomized, double-blind trial, we evaluated the efficacy of infliximab monotherapy, azathioprine monotherapy, and the two drugs...

  • TxCell Lands $16M to Advance Immunotherapy for Crohn's. Sheridan, Cormac // BioWorld International;11/28/2012, Vol. 17 Issue 48, p3 

    The article reports on a Series C round completed by TxCell SA to fund a Phase IIb study of its OvaSave autologous cell therapy in patients with refractory Crohn's disease. The company raised 12.4 million euros from the financing round. According to chief executive officer (CEO) Francois Meyer,...

  • Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Sandborn, W. J.; Hanauer, S. B.; Rutgeerts, P.; Fedorak, R. N.; Lukas, M.; MacIntosh, D. G.; Panaccione, R.; Wolf, D.; Kent, J. D.; Bittle, B.; Li, J.; Pollack, P. F. // Gut;Sep2007, Vol. 56 Issue 9, p1232 

    Background: Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease in the CLASSIC I trial. Objective: To evaluate long term efficacy and safety of adalimumab maintenance therapy in Crohn's disease in a follow-on randomised controlled trial (CLASSIC II)....

  • Antibacterial Therapies in IBD: Present and Future. Pineton de Chambrun, Guillaume P.; Torres, Joana; Darfeuille-Michaud, Arlette; Colombel, Jean-Frédéric // Inflammatory Bowel Disease Monitor;2012, Vol. 12 Issue 3, p89 

    The etiology of IBD is unknown but may relate to an unidentified bacterial pathogen or an aberrant immunological reaction to the gut microbiota. Antibiotics have therefore been proposed as a therapy to induce remission in active disease and to prevent relapse. Although the current data are...

  • Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn's disease.  // Inflammatory Bowel Disease Monitor;2012, Vol. 13 Issue 2, p68 

    Hanai et al. studied 95 adult patients with Crohn's disease in clinical remission who were randomly assigned to mercaptopurine (n=30), partial elemental diet (n=32), or no active treatment (n=33). At 2 years of follow-up, 17 of 30 (57%) mercaptopurine, 14 of 32 (44%) elemental diet, and seven of...

  • Ustekinumab induction and maintenance therapy in refractory Crohn's disease.  // Inflammatory Bowel Disease Monitor;2012, Vol. 13 Issue 2, p69 

    In this important paper, the CERTIFI (Crohn's Evaluation of Response to Ustekinumab Anti-Interleukin-12/-23 for Induction) study group present the results of the prospective, randomized controlled trial of the interleukin-12/-23 monoclonal antibody ustekinumab in the treatment of...


Read the Article


Sign out of this library

Other Topics